Enhanced cisplatin therapy for ovarian cancer cell lines
收藏官方服务：
资源简介：
Enhanced cisplatin therapy for ovarian cancer cell lines
应用场景：
创建时间：
2013-12-31
相关数据集
Ovarian cancer-related target proteins/genes
Ovarian cancer-related target proteins/genes
NIAID Data Ecosystem40
p53-PIK3CA in HGSOC. Deciphering Mutant p53-PIK3CA Nexus: Opportunities for Targeted Therapy in High-Grade Serous Ovarian Cancer
High-Grade Serous Ovarian Cancer (HGSOC), the most prevalent ovarian cancer subtype, currently treated with platinum-taxol-based chemotherapy, has a dismal five-year survival rate (>30%). Emergence of
NIAID Data Ecosystem20
Targeting meiotic recombination 11 (MRE11) nuclease for personalization of epithelial ovarian cancer therapy
Platinum resistance is a clinical challenge in ovarian cancer. Platinating agents induce DNA damage which activate Mre11 nuclease directed DNA damage signalling and response (DDR). Upregulation of DDR
NIAID Data Ecosystem00
PARG inhibitor sensitivity correlates with accumulation of single strand DNA gaps in preclinical models of ovarian cancer
Poly (ADP-ribose) glycohydrolase (PARG) is a dePARylating enzyme which promotes DNA repair by removal of poly (ADP-ribose) (PAR) from PARP1-parylated proteins. Loss or inhibition of PARG results in r
NIAID Data Ecosystem20
DataSheet1_GSK-J1-loaded, hyaluronic acid-decorated metal-organic frameworks for the treatment of ovarian cancer.docx
Despite intensive research, ovarian cancer has the highest mortality rates among gynecological malignancies, partly because of its rapid acquisition of chemoresistance to platinum therapy. Hence, stra
NIAID Data Ecosystem10
